Clinic variation in the cost-effectiveness of contingency management

American Journal on Addictions

Volumn 16, Issue 6, 2007, Pages 457-460

  Olmstead, Todd A ^a   Sindelar, Jody L ^b,c   Petry, Nancy M ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTINGENT VALUATION; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT DEPARTMENT; PATIENT CARE; TREATMENT DURATION;

BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATA COLLECTION; HEALTH CARE COSTS; HUMANS; META-ANALYSIS AS TOPIC; PROBABILITY; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 36848998766     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701643062     Document Type: Article

References (23)

1. Petry NM, Pierce J, Stitzer ML, et al. Prize-based incentives improve outcomes of stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2005;62:1148-1156.
2. Peirce JM, Petry NM, Stitzer ML, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network Study. Arch Gen Psychiatry. 2006;63:201-208.
3. Higgins ST, Sigmon SC, Wong CJ, et al. Community reinforcement therapy for cocaine-dependent outpatients. Arch Gen Psychiatry. 2003;60:1043-1052.
4. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry. 2002;59:817-824.
5. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051-1061.
6. Petry NM, Martin B, Cooney JL, Kranzler HR. Give them prizes and they will come: Contingency management for the treatment of alcohol dependence. J Consult Clin Psychol. 2000;68:250-257.
7. Petry NM, Tedford J, Austin M, Nich C, Carroll K, Rounsaville B. Prize reinforcement contingencymanagement for treating cocaine user: how low can we go, and with whom? Addiction. 2004;99:349-360.
8. Petry NM, Martin B. Lower-cost contingency management for treating cocaine-abusing methadone patients. J Consult Clin Psychol. 2002;70:398-405.
9. Ritter A, Cameron J. Australian clinician attitudes towards contingency management: comparing down under with America. Drug Alcohol Depend. 2007;87:312-315.
10. Carroll KM, Rounsaville BJ. Bridging the gap between research and practice in substance abuse treatment: a hybrid model linking efficacy and effectiveness research. Psychiatr Serv. 2003;54:333-339.
11. Petry NM. A comprehensive guide for the application of contingency management procedures in standard clinic settings. Drug Alcohol Depend. 2000;58:9-25.
12. Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend. 2007;87:175-182.
13. Sindelar JL, Elbel B, Petry NM. What do we get for our money? Cost-effectiveness of adding contingency management. Addiction. 2007;102:309-316.
14. French MT, Mausopf JA, Teague JL, Roland J. Estimating the dollar value of health outcomes from drug abuse interventions. Med Care. 1996;34:890-910.
15. Cartwright WS. Cost benefit and cost-effectiveness analysis of drug abuse treatment services. Eval Rev. 1998;22:609-636.
16. Cartwright WS. Cost-benefit analysis of drug treatment services: Review of the literature. J Ment Health Policy Econ. 2000;3:11-26.
17. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96:1267-1278.
18. Jofre-Bonet M, Sindelar JL. Creating an aggregate outcome index: cost-effectiveness analysis of substance abuse treatment. J Behav Health Serv Res. 2004;31:229-241.
19. Sindelar JL, Jofre-Bonet M, French MT, McLellan AT. Cost-effectiveness analysis of addition treatments for illicit drug dependence: paradoxes with multivariate outcomes. Drug Alcohol Depend. 2004;73:41-50.
20. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. Oxford, UK: Oxford University Press; 1997.
21. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
22. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press; 2001:172-214.
23. Fenwick E, Claxton K, Schulpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.